2
Announcements
Trials
Browse
Landscape
Phase
Phase 3
2
Status
Active not recruiting
2
Sponsor Class
INDUSTRY
2
Study Type
Interventional
2
Sponsor
Cancer Type
Breast
2
Conditions
Breast Neoplasms
14
Neoplasm Metastasis
3
Neoplasms by Site
2
Neoplasms
2
Breast Diseases
2
Advanced Breast Cancer
2
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Skin Diseases
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Lymphoma, Follicular
1
Endometrial Neoplasms
1
ER+ HER2- Advanced Breast Cancer
1
Colorectal Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Biliary Tract Neoplasms
1
Interventions
Anastrozole
8
exemestane
7
Trastuzumab
7
Letrozole
7
palbociclib
6
Docetaxel
6
abemaciclib
5
Fulvestrant
5
ribociclib
4
pyrotinib
4
entinostat
4
Cyclophosphamide
4
Tamoxifen
3
Doxorubicin
3
pertuzumab
2
Sodium Chloride
2
Paclitaxel
2
Lapatinib
2
Gonadotropin-Releasing Hormone
2
Exercise
2
Everolimus
2
Epirubicin
2
Drug Evaluation
2
Capecitabine
2
Botulinum Toxins, Type A
2
Blood Specimen Collection
2
Aromatase Inhibitors
2
AZD9833
2
tucatinib
1
trastuzumab deruxtecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Breast Diseases
×
AZD9833
×
Clear all
NCT04964934
2026-04-21
SERENA-6
AstraZeneca
Phase 3
Active not recruiting
315 enrolled
NCT04711252
2025-10-14
SERENA-4
AstraZeneca
Phase 3
Active not recruiting
1,370 enrolled